Safety profile and pharmacokinetics of a synthetic cannabinoid (JHW-018) - Sythetic cannabinoid

niversiteit Maastricht0 个研究点目标入组 55 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•* Used cannabis between 2 times a month and 2 times a week during the previous year
•* Age between 18 and 40 years
•* Free from psychotropic medication
•* the subject is, in the opinion of the investigator, generally healthy based on assessment of medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests
•* clinical laboratory test values within the reference ranges. Borderline values may be accepted if they are, in the opinion of the investigator, clinically insignificant.
•* normal binocular visual acuity, corrected or uncorrected
•* Absence of any major medical, endocrine and neurological condition, as determined by the medical history, medical examination, electrocardiogram and laboratory analyses (haematology, clinical chemistry, urinalysis, serology).
•* Normal weight, body mass index (weight/height2) between 19,5 and 28 kg/m2
•* Written Informed Consent

•* History of drug abuse (other than the use of cannabis) or addiction (determined by the medical questionnaire, drug questionnaire and medical examination)
•* Experience with synthetic cannabis
•* Pregnancy or lactation
•* Hypertension (diastolic> 90; systolic> 140)
•* Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination)
•* Liver dysfunction
•* (Serious) side effects to previous cannabis use
•* History of cardiac dysfunctions (arrhythmia, ischemic heart disease,*)
•* Simultaneous participation in another clinical trial
•* For women: no use of a reliable contraceptive

发起方